Daily iron supplementation for prevention or treatment of moderate iron deficiency anemia in patients with solid neoplasm, undergoing concurrent radiochemotherapy treatment
Sucrosomial<sup>®</sup> oral iron formulation seems to be efficient in preventing moderate and severe anemia during long-course randomized controlled trial (RCT) in cancer patients, while also offering notable advantages in terms of quality of life and healthcare costs.
Authors
- Giorgia Marano
- Rocco Luca Emanuele Liardo (ORCID: https://orcid.org/0009-0007-0458-601X)
- Irene Finocchiaro (ORCID: https://orcid.org/0009-0008-0085-423X)
- Corrado Spatola (ORCID: https://orcid.org/0000-0001-5562-189X)
- Maria Chiara Lo Greco (ORCID: https://orcid.org/0000-0003-4294-7350)
- Roberto Milazzotto (ORCID: https://orcid.org/0000-0003-3282-2204)
- Madalina La Rocca (ORCID: https://orcid.org/0000-0002-7933-3056)
- Arianna Iudica
- Barbara Francesca Leonardi
Institutions
- University of Messina (IT)
- University of Catania (IT)
- Policlinico Universitario di Catania (IT)
Publication Details
- Journal
- Reports of Practical Oncology & Radiotherapy
- Published
- 2025-10-03
- DOI
- https://doi.org/10.5603/rpor.107743
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00